Anthea Peters

786 total citations
49 papers, 513 citations indexed

About

Anthea Peters is a scholar working on Oncology, Pathology and Forensic Medicine and Genetics. According to data from OpenAlex, Anthea Peters has authored 49 papers receiving a total of 513 indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 27 papers in Pathology and Forensic Medicine and 14 papers in Genetics. Recurrent topics in Anthea Peters's work include Lymphoma Diagnosis and Treatment (24 papers), Viral-associated cancers and disorders (16 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Anthea Peters is often cited by papers focused on Lymphoma Diagnosis and Treatment (24 papers), Viral-associated cancers and disorders (16 papers) and Chronic Lymphocytic Leukemia Research (14 papers). Anthea Peters collaborates with scholars based in Canada, United States and Germany. Anthea Peters's co-authors include Raymond Lai, Sunita Ghosh, Douglas A. Stewart, Mona Anand, Pascal Gélébart, Susan E. Andrew, Hesham M. Amin, Jennifer Dien Bard, Robert Puckrin and Carolyn Owen and has published in prestigious journals such as Blood, Gastroenterology and Clinical Cancer Research.

In The Last Decade

Anthea Peters

41 papers receiving 505 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Anthea Peters Canada 14 245 237 168 72 67 49 513
Willi Woessmann Germany 14 439 1.8× 215 0.9× 156 0.9× 58 0.8× 100 1.5× 20 656
Lukas Marcelis Belgium 12 140 0.6× 186 0.8× 102 0.6× 57 0.8× 98 1.5× 26 487
Hiroshi Gomyo Japan 10 233 1.0× 207 0.9× 61 0.4× 47 0.7× 126 1.9× 19 386
Julie C. Porcher United States 8 213 0.9× 126 0.5× 106 0.6× 71 1.0× 69 1.0× 13 399
Stephan Kreher Germany 15 216 0.9× 160 0.7× 174 1.0× 160 2.2× 251 3.7× 26 700
JL Huret France 6 301 1.2× 166 0.7× 126 0.8× 128 1.8× 91 1.4× 100 521
J. Kimble Frazer United States 12 134 0.5× 214 0.9× 355 2.1× 37 0.5× 193 2.9× 33 684
Anna Llort Spain 10 103 0.4× 139 0.6× 161 1.0× 73 1.0× 23 0.3× 19 449
Robert Lowsky Canada 11 218 0.9× 155 0.7× 211 1.3× 63 0.9× 46 0.7× 16 529
Maria Antonella Laginestra Italy 12 151 0.6× 144 0.6× 147 0.9× 56 0.8× 82 1.2× 25 382

Countries citing papers authored by Anthea Peters

Since Specialization
Citations

This map shows the geographic impact of Anthea Peters's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anthea Peters with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anthea Peters more than expected).

Fields of papers citing papers by Anthea Peters

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anthea Peters. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anthea Peters. The network helps show where Anthea Peters may publish in the future.

Co-authorship network of co-authors of Anthea Peters

This figure shows the co-authorship network connecting the top 25 collaborators of Anthea Peters. A scholar is included among the top collaborators of Anthea Peters based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anthea Peters. Anthea Peters is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shahbaz, Shima, et al.. (2025). Polyfunctional CD 8 + CD 226 + RUNX 2 hi effector T cells are diminished in advanced stages of chronic lymphocytic leukemia. Molecular Oncology. 19(5). 1347–1370. 1 indexed citations
2.
Boer, A. de, et al.. (2025). Evaluating the impact of a pharmacist-led venetoclax ramp-up clinic for chronic lymphocytic leukemia patients: A retrospective chart review. Journal of Oncology Pharmacy Practice. 3222358122–3222358122.
3.
Peters, Anthea, et al.. (2025). Lysosome targeted therapies in hematological malignancies. Frontiers in Oncology. 15. 1549792–1549792. 1 indexed citations
4.
5.
Puckrin, Robert, Carolyn Owen, & Anthea Peters. (2024). Underrepresentation of Small Lymphocytic Lymphoma in Clinical Trials for Chronic Lymphocytic Leukemia. European Journal Of Haematology. 114(4). 636–640.
6.
Banerji, Versha, Andrew Aw, Nicole Laferriere, et al.. (2024). Management and use of healthcare resources in patients with chronic lymphocytic leukemia initiating venetoclax in routine clinical practice. Leukemia & lymphoma. 65(5). 609–617.
7.
Bozorgmehr, Najmeh, et al.. (2023). Depletion of polyfunctional CD26highCD8+ T cells repertoire in chronic lymphocytic leukemia. Experimental Hematology and Oncology. 12(1). 13–13. 22 indexed citations
8.
Peters, Anthea, et al.. (2023). Management of Marginal Zone Lymphoma: A Canadian Perspective. Current Oncology. 30(2). 1745–1759.
9.
Nowakowski, Grzegorz S., Dok Hyun Yoon, Anthea Peters, et al.. (2022). Improved Efficacy of Tafasitamab plus Lenalidomide versus Systemic Therapies for Relapsed/Refractory DLBCL: RE-MIND2, an Observational Retrospective Matched Cohort Study. Clinical Cancer Research. 28(18). 4003–4017. 16 indexed citations
10.
Anaka, Matthew, et al.. (2021). Filgrastim-Induced Bone Pain Is More Prevalent and Severe during Stem Cell Mobilization. Transplantation and Cellular Therapy. 27(3). S374–S375.
11.
Alshareef, Abdulraheem, et al.. (2021). Gene Methylation and Silencing of WIF1 Is a Frequent Genetic Abnormality in Mantle Cell Lymphoma. International Journal of Molecular Sciences. 22(2). 893–893. 1 indexed citations
12.
Li, Jing, Christopher P. Venner, Irwindeep Sandhu, et al.. (2021). Three-Dimensional Reconstructed Bone Marrow Matrix Culture Improves the Viability of Primary Myeloma Cells In-Vitro via a STAT3-Dependent Mechanism. Current Issues in Molecular Biology. 43(1). 313–323. 4 indexed citations
13.
Bozorgmehr, Najmeh, Isobel Okoye, Lai Xu, et al.. (2021). Expanded antigen-experienced CD160+CD8+effector T cells exhibit impaired effector functions in chronic lymphocytic leukemia. Journal for ImmunoTherapy of Cancer. 9(4). e002189–e002189. 34 indexed citations
14.
Assouline, Sarit, Lilian Amrein, Raquel Aloyz, et al.. (2020). IND.216: a phase II study of buparlisib and associated biomarkers, raptor and p70S6K, in patients with relapsed and refractory chronic lymphocytic leukemia. Leukemia & lymphoma. 61(7). 1653–1659. 6 indexed citations
15.
Stubbins, Ryan J., et al.. (2020). Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes. Leukemia & lymphoma. 61(14). 3319–3330. 6 indexed citations
16.
Stubbins, Ryan J., Anthea Peters, Simon Urschel, et al.. (2018). Epstein‐Barr virus associated smooth muscle tumors in solid organ transplant recipients: Incidence over 31 years at a single institution and review of the literature. Transplant Infectious Disease. 21(1). e13010–e13010. 22 indexed citations
17.
Molavi, Ommoleila, Abdulraheem Alshareef, Qian Wang, et al.. (2018). Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model. Cancers. 10(6). 206–206. 20 indexed citations
18.
19.
Peters, Anthea, Annette Breedijk, Wilhelm H. Schmitt, et al.. (2009). Retinoid X receptor beta polymorphisms do not explain functional differences in vitamins D and A response in Antineutrophil cytoplasmic antibody associated vasculitis patients. Autoimmunity. 42(5). 467–474. 8 indexed citations
20.
Andrew, Susan E. & Anthea Peters. (2001). DNA Instability and Human Disease. PubMed. 1(1). 21–28. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Willi Woessmann Breakdown of academic impact, for papers by Lukas Marcelis Breakdown of academic impact, for papers by Hiroshi Gomyo Breakdown of academic impact, for papers by Julie C. Porcher Breakdown of academic impact, for papers by Stephan Kreher Breakdown of academic impact, for papers by JL Huret Breakdown of academic impact, for papers by J. Kimble Frazer Breakdown of academic impact, for papers by Anna Llort Breakdown of academic impact, for papers by Robert Lowsky Breakdown of academic impact, for papers by Maria Antonella Laginestra
Rankless by CCL
2026